Changmao Biochemical Engineering Co. Ltd. Class H

Changmao Biochemical Engineering Co. Ltd. Class H

HHKEX:954
0.23
HKD
0.00
(0.00%)
153.84MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.33
1.06
0.97
1.12
1.19
1.21
0.93
0.84
1.03
1.38
1.2
1.1
1.05
- -
Basic EPS, GAAP
0.13
0.07
0.09
0.06
0.01
0.1
0.11
0.03
0.11
0.15
-0.16
-0.13
-0.13
- -
Free Cash Flow per Basic Share
0.02
0.06
0.08
0.04
0.03
0.02
0.15
-0.04
-0.49
-0.38
-0.27
-0.18
0.02
- -
Dividend per Share
0.03
0.04
0.02
0.03
0.02
- -
0.05
0.06
0.02
- -
0.08
- -
- -
- -
Book Value per Share
0.98
1.01
1.07
1.11
1.09
1.19
1.25
1.23
1.32
1.47
1.23
1.1
0.98
0.97
Tangible Book Value per Share
0.93
0.95
1.02
1.05
1.04
1.14
1.2
1.18
1.13
1.29
1.06
0.93
0.81
0.97
Basic Weighted Avg Shares
530
530
530
530
530
530
530
530
530
530
530
530
530
530
Sales/Revenue/Turnover
703
562
515
594
631
639
495
444
548
730
637
585
557
- -
Operating Margin (%)
12.28
8.03
8.39
4.84
1.13
8.4
12.92
4.75
-7
11.96
-7.97
-9.91
-9.28
- -
Depreciation Expense
35
34
37
36
38
34
35
33
29
32
43
46
54
- -
Net Income, GAAP
70
37
45
33
3
51
58
17
58
81
-86
-68
-67
- -
Effective Tax Rate (%)
13.82
10.73
11.49
4.27
- -
8.59
7.4
2.38
31.04
7.17
- -
- -
- -
- -
Profit Margin (%)
9.96
6.63
8.79
5.58
0.54
7.91
11.79
3.79
10.64
11.15
-13.51
-11.67
-11.99
- -
Working Capital
147
131
167
190
167
213
238
213
60
88
13
-306
-276
-289
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
2
153
251
21
61
52
Total Equity
520
536
569
589
581
631
662
650
698
779
652
583
516
511
Return on Invested Capital (%)
12.35
6.43
6.93
5.16
- -
7.76
8.56
2.48
8.19
8.89
- -
- -
- -
- -
Return on Capital (%)
12.35
6.57
7.07
5.18
- -
8
8.74
2.54
8.32
9.04
- -
- -
- -
- -
Return on Common Equity (%)
14.29
7.08
8.23
5.75
0.58
8.36
9.03
2.57
8.66
11.04
-12.03
-11.05
-12.14
- -

Capital Structure

CNY

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
488
479
436
LT Borrowings
47
60
52
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
530
530
530
Market Capitalization
147
136
133

Working Capital

CNY

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
292
271
231
Cash, Cash Equivalents & STI
66
72
40
Accounts Receivable, Net
48
56
46
Inventories
136
110
117
Total Current Liabilities
584
547
519
Payables & Accruals
- -
- -
- -
ST Debt
488
479
436
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-0.55%
-3.86%
-11.51%
Free Cash Flow
129.17%
190.61%
-111.1%
Net Income, GAAP
127.93%
11.53%
-2.17%
Sales/Revenue/Turnover
2.1%
6.18%
-4.77%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
585
2025
- -
- -
557
2026
- -
- -
- -

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.13
2025
- -
- -
-0.13
2026
- -
- -
- -

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

CEO
Chun Pan
Full Time Employees
518
Sector
Process industries
Industry
Chemicals: specialty
Address
No. 1228 Chang Jiang Bei Road Changzhou JS China 213034
IPO Date
Jun 28, 2002
Business
Changmao Biochemical Engineering Company Limited (0954.HK) manufactures and markets four-carbon organic acids and derivatives principally for food additives, pharmaceuticals, chemicals, biomedicine, new materials and agriculture applications; core products include L-malic acid, DL-malic acid, L(+)-tartaric acid, D-tartaric acid, DL-tartaric acid, fumaric acid, maleic acid, aspartic acid, aspartame, cream of tartar, sodium pantothenate, pyrroloquinoline quinone (PQQ), L(+)-diethyl L-tartrate, diethyl L-malate, dimethyl L-malate and 1,2,3,4-butanetetracarboxylic dianhydride. Founded in 1992 and headquartered in Changzhou, Jiangsu Province, China, the company operates production facilities through subsidiaries including Shanghai Changmao Biochemical Engineering Company Limited, Changmao Biochemical Lianyungang Company Limited and Changmao (Dalian) New Materials Company Limited, with sales networks spanning Mainland China, Europe, Asia Pacific, the United States and other regions; it maintains research centers such as the Chirotechnology Centre in Changzhou and Shanghai Medical Life Science Research Centre Limited ("Shanghaimed"). The company listed on the Hong Kong GEM board in 2002 before transferring to the Main Board in 2013, achieved milestones including the first butane-maleic anhydride production line in Jiangsu Province in 2017 and establishment of the Dalian facility in 2020, and in 2024 launched 14 new R&D projects, secured one new invention patent, filed three additional patent applications, completed registration of one new pharmaceutical excipient alongside multiple raw material and excipient registrations, and advanced key import substitution initiatives while supporting Dalian plant scale-up for chemical production, nutraceuticals, APIs, feed additives and electronic-grade chemicals amid reported revenue of CNY543 million and net losses.